Drugs / A2B395
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06682793 | May 2025 → Mar 2029 expected | colon carcinoma, colorectal adenocarcinoma, head and neck squamous cell carcinoma, non-small cell lung carcinoma +3 | A2 Biotherapeutics Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-06-26 | A2 Biotherapeutics Inc. | Results A2 Biotherapeutics Announces First Patient Dosed in DENALI-1 Phase 1/2 Clinical Study of A2B395, a Novel Allogeneic Precision CAR T Cell Therapy for Patients with Solid Tumors that Express EGFR a2bio.com ↗
A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage cell therapy company developing first-in-class logic-gated cell therapies for solid tumors, today announced dosing of the first patient in the DENALI-1 ( NCT06682793 ) clinical study. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-09-15 | A2 Biotherapeutics Inc. | A2 Biotherapeutics Announces Findings from DENALI-1 Study of A2B395 Precision CAR T-Cell Therapy for Patients with Solid Tumors Expressing EGFR a2bio.com ↗ |
| 2025-06-26 | A2 Biotherapeutics Inc. | A2 Biotherapeutics Announces First Patient Dosed in DENALI-1 Phase 1/2 Clinical Study of A2B395, a Novel Allogeneic Precision CAR T Cell Therapy for Patients with Solid Tumors that Express EGFR a2bio.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | A2B395 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06682793 ↗ |
| Action | Deplete | “A2B395 Tmod CAR T-cell therapy will enable the killing of tumor target cells” NCT06682793 ↗ |
| Modality | Cell therapy | “A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product” NCT06682793 ↗ |
| Route | Intravenous | “single dose of A2B395 intravenously on day 0” NCT06682793 ↗ |